Adam Levy Buys 8,832 Shares of Acrivon Therapeutics (NASDAQ:ACRV) Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) CFO Adam Levy purchased 8,832 shares of the business’s stock in a transaction dated Wednesday, January 14th. The shares were acquired at an average price of $1.70 per share, for a total transaction of $15,014.40. Following the acquisition, the chief financial officer directly owned 20,983 shares in the company, valued at $35,671.10. This represents a 72.69% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Acrivon Therapeutics Trading Up 5.9%

Shares of NASDAQ:ACRV opened at $1.98 on Friday. The stock has a market capitalization of $62.49 million, a PE ratio of -0.93 and a beta of 1.73. Acrivon Therapeutics, Inc. has a 1 year low of $1.05 and a 1 year high of $8.00. The firm has a fifty day moving average price of $2.30 and a 200 day moving average price of $1.82.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its earnings results on Thursday, November 13th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.10. On average, sell-side analysts forecast that Acrivon Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd acquired a new position in shares of Acrivon Therapeutics during the second quarter valued at about $26,000. Focus Partners Wealth bought a new position in Acrivon Therapeutics during the third quarter valued at about $36,000. Invesco Ltd. bought a new position in Acrivon Therapeutics during the first quarter valued at about $72,000. Algert Global LLC acquired a new position in Acrivon Therapeutics in the 3rd quarter valued at approximately $81,000. Finally, XTX Topco Ltd bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter worth approximately $126,000. Institutional investors own 71.62% of the company’s stock.

Wall Street Analysts Forecast Growth

ACRV has been the topic of a number of recent analyst reports. Piper Sandler lifted their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Wall Street Zen lowered shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Acrivon Therapeutics in a report on Tuesday, November 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.